Healthcare Resource Utilization Among Adults With Pneumococcal Disease in England 2017-2022: A Retrospective Database Analysis

Author(s)

M. Doyinsola Bailey, BSc, MPH, PhD1, Amanda Martino, BA, MPH1, John J. Were, MPH2, Sariga Kakkamani, MSc3, Rafael Coderch Lanau, MSc4, Georgia Yates, MSc2, Yi Zheng, MPH, PhD1, Yi-Ling Huang, PhD1, Valina C McGuinn, BS1, Ian Matthews, BSc, MSc, PhD5, Smit Patel, BSc, MSc5, Dionysios Ntais, MSc5, Salini Mohanty, BS, MPH, DrPH1, Kelly D. Johnson, BS, MPH, PhD1.
1Merck & Co., Inc., Rahway, NJ, USA, 2Parexel International, London, United Kingdom, 3Parexel International, Brussels, Belgium, 4Parexel, Austin, TX, USA, 5MSD (UK) Ltd, London, United Kingdom.
OBJECTIVES: This study estimated the national and regional economic burden of pneumococcal disease (PD) among adults in England by age and risk group.
METHODS: A retrospective study using linked data from the Clinical Practice Research Datalink and Hospital Episodes Statistics Admitted Patient Care databases was conducted among adults ≥18 years old diagnosed with PD between 2017-2022. All-cause healthcare resource utilization was measured as the annual mean number of inpatient, outpatient, and primary care visits, along with annual total and per-patient costs. Results were stratified by PD manifestation (invasive PD (IPD), non-bacteremic pneumococcal pneumonia (NBPP), all-cause pneumonia (ACP)), age group (18-49, 50-64, ≥65 years), risk group (high, moderate, low), and region.
RESULTS: The analysis included an average of 195,475 PD patients annually. Most (89%) were admitted as inpatients, averaging 3.4 episodes per patient per year. Additionally, 76% had an average of 4.7 outpatient visits, and 52% had 9.5 primary care consultations. Annual costs were analyzed for an average of 132,708 inpatient patients (£1,840 million, £13,865/patient), 53,721 outpatient patients (£24 million, £438/patient), and 101,594 primary care patients (£26 million, £259/patient). Total costs were highest for ACP (£1,857 million), patients aged 65+ (£1,484 million), moderate-risk patients (£1,028 million), and those in North West England (£385 million).
CONCLUSIONS: Healthcare utilization for adults with PD in England remains significant, with the highest costs associated with ACP, older adults (≥65 years) and moderate-risk individuals. Inpatient admissions accounted for a considerable proportion of healthcare costs.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

EE510

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Vaccines

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×